Aardvark Therapeutics is a biotechnology company that aims to develop treatments for metabolic and inflammatory diseases. Specifically, the company focuses on its small molecule therapeutics that have a mission to help activate the gut-to-brain signaling pathways related to hunger and appetite suppression. The company’s main product candidate ARD-101 is an oral compound that aims to act as a bitter taste receptor with the goal of reducing appetite and promoting weight loss. Aardvark Therapeutics was founded in 2017 by Andreas Niethammer and Tien Lee and is headquartered in San Diego, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/09/2024 | Series C | $85MM | $xx.xx | $267.58MM | Decheng Capital, Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG Technology Ventures, Cantor Ventures, Silver Arc Private Capital, Prader-Willi Syndrome Association, Vickers Venture Partners, Foundation for Prader-Willi Research | |
Price per Share
$xx.xx
Shares Outstanding
48,030,730
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Decheng Capital, Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG Technology Ventures, Cantor Ventures, Silver Arc Private Capital, Prader-Willi Syndrome Association, Vickers Venture Partners, Foundation for Prader-Willi Research
|
||||||
08/05/2021 | Series B | $29.13MM | $xx.xx | $114.34MM | Sorrento Therapeutics, Vickers Venture Partners, Premier Partners, BNH Investment, Korea Omega, Foundation for Prader-Willi Research | |
Price per Share
$xx.xx
Shares Outstanding
22,660,592
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Sorrento Therapeutics, Vickers Venture Partners, Premier Partners, BNH Investment, Korea Omega, Foundation for Prader-Willi Research
|
||||||
11/29/2019 | Series A | $15MM | $xx.xx | $42.86MM | Vickers Venture Partners, Premier Partners, BNH Investment, Korea Omega, Dreavent Capital | |
Price per Share
$xx.xx
Shares Outstanding
26,250,131
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Vickers Venture Partners, Premier Partners, BNH Investment, Korea Omega, Dreavent Capital
|